Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

BACKGROUND: Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who received at least two prior regimens. However, there are no reliable data regarding AGC patients with poor performance status (PS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Toshihiko, Yamamoto, Yosuke, Kuriona, Yusuke, Okazaki, Ukyo, Kimura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Mastumoto, Yusuke, Takatani, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376661/
https://www.ncbi.nlm.nih.gov/pubmed/32698781
http://dx.doi.org/10.1186/s12885-020-07176-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376661/
https://www.ncbi.nlm.nih.gov/pubmed/32698781
http://dx.doi.org/10.1186/s12885-020-07176-7

Ejemplares similares